Best Peptides for Weight Loss in 2026 (Ranked by Clinical Data)

• •Primary metric: average % body weight lost in Phase 2/3 clinical trials at the longest reported follow-up.
• •Safety tier: FDA-approved compounds rank above approved-in-other-markets, which rank above experimental compounds — for equal weight loss.
• •Practicality: titration complexity, side-effect burden, and monitoring requirements.
• •Every compound here is for research or medically supervised use — none of this is a consumer supplement recommendation.

The pattern is unmistakable: every top compound is an incretin (GLP-1-family) agonist. Dual and triple agonists dominate because they attack appetite through multiple satiety pathways at once. Below, what each one is and who it fits.

Retatrutide activates three receptors: GLP-1 (fullness), GIP (insulin/lipid), and glucagon (energy expenditure and hepatic fat breakdown). Its Phase 3 program reported 28.3% average body weight loss at 80 weeks — numbers that overlap with bariatric surgery. Full dosing and cycle details: the retatrutide guide.

Who it fits: research settings and supervised protocols where maximum effect matters and long-term safety uncertainty is acceptable. Not for a first protocol, not for anyone who cannot commit to slow titration (1 → 12 mg over ~20 weeks).

Cagrisema is semaglutide plus cagrilintide (an amylin analog) in one weekly injection — the first commercialized example of stacking two satiety pathways (GLP-1 + amylin) into a single protocol. The REDEFINE program projects ~25% average loss. Its full peptide page covers the dual-component dosing (titrate both components slowly).

Tirzepatide (Zepbound) delivers 20.9% average loss at 72 weeks in SURMOUNT-1 with the best side-effect-to-benefit ratio in the class — the GIP component seems to soften the GLP-1 GI burden. Titration: 2.5 → 15 mg in 2.5 mg steps every 4 weeks; many protocols cap at 7.5–10 mg where most of the benefit concentrates. See also the semaglutide vs tirzepatide head-to-head and the tirzepatide guide.

Who it fits: anyone in a medically supervised protocol wanting the strongest effect with a known, regulatory-reviewed safety profile. This is the pragmatic #1 for most people.

Survodutide (GLP-1 + glucagon, ~19% in Phase 2, also in Phase 3 for fatty liver) and mazdutide (GLP-1 + glucagon, ~15% at 9 mg in China's GLORY-1, approved in China) show the glucagon pathway adds meaningful loss on top of GLP-1. Semaglutide — the original STEP-trial gold standard at ~15% with the deepest long-term cardiovascular data — remains the most data-rich choice and the backbone of Cagrisema. Full details: the semaglutide guide.

As a single agent cagrilintide produces ~10% loss — mid-table. Its importance is as a stack partner: added to semaglutide it forms Cagrisema, and added to any GLP-1 it introduces satiety signaling that does not cross-desensitize with GLP-1 receptors. That is a textbook complementary-pathway stack.

Every incretin is a once-weekly subcutaneous injection with a slow titration front — but the paths differ meaningfully:

Never combine two incretin agonists in the same week — they share receptor pathways and stack toxicity, not results. For your weight, target loss, and history, the protocol builder computes the titration schedule, cycle calendar, and safety screening automatically — and the GLP-1 dosing timeline guide walks the week-by-week mechanics.

A second tier of peptides does not touch the incretin system. They are weaker as primaries but appear in stacks for their fat-specific and muscle-preserving mechanisms:

Honest framing: none of these approach incretin-tier results as standalone agents. They are stack candidates, and in the protocol engine they are only ever recommended alongside — never instead of — a primary peptide.

Trial averages hide enormous individual spread — the standard deviation on mean weight loss is large, meaning many participants lose meaningfully more than the average and many lose less. The realistic pattern across trials: faster loss in the first 12–20 weeks (5–10% is common in that window), then a slower linear phase as the dose stabilizes and the body adapts. Non-responders exist at meaningful rates in every trial — if a full titration at a comfortable dose produces <5% loss, the answer is a supervised re-evaluation (dose, adherence, diagnosis), not doubling down or stacking compounds.

Also keep the loss in perspective: at 15–20% body weight loss, trial participants show big improvements in blood pressure, lipids, and glycemic markers — outcomes that matter more to long-term health than the scale number. Whatever compound you research, protein intake (~1.6 g/kg) and resistance training are what decide how much of the lost weight is fat rather than muscle.

The incretin side-effect profile is dominated by the GI tract: nausea (the most common), vomiting, diarrhea, and constipation, plus slowed stomach emptying that makes large meals uncomfortable. Severity tracks the titration schedule far more than the molecule — patients who step up doses slowly report dramatically fewer problems. Rarer but serious class risks: gallbladder events (driven by rapid weight loss itself), pancreatitis, and a warning history for medullary thyroid carcinoma/MEN2.

Non-incretin compounds carry their own flags: tesofensine has a narrow cardiovascular margin (blood pressure and heart rate), and 5-Amino-1MQ/AOD-9604 have minimal human data at all. The peptide safety guide covers screening, lab work, and escalation rules across every category.

• •Weight to lose under 15% of body weight → semaglutide or tirzepatide at moderate titration depth.
• •Higher starting BMI / >20% to lose → tirzepatide first; retatrutide only in research settings.
• •Plateau on a single GLP-1 → ask about pathway additions (amylin) rather than dose-stacking the same pathway.
• •Any history of pancreatitis, medullary thyroid carcinoma/MEN2, or gastroparesis → the entire incretin class is contraindicated; the engine screens these out automatically.
• •Always: titrate slowly, cycle 16–24 weeks with planned breaks, and maintain protein + resistance training throughout.